Evidence map›Paper›PMID 37459088›Full record

ArticleJAMA neurology2023

Excess Mortality With Alzheimer Disease and Related Dementias as an Underlying or Contributing Cause During the COVID-19 Pandemic in the US.

Ruijia Chen, Marie-Laure Charpignon, Rafeya V Raquib, Jingxuan Wang, Erika Meza, Hélène E Aschmann, Michelle A DeVost, Alyssa Mooney, Kirsten Bibbins-Domingo, Alicia R Riley and 4 more

Open access · hybridAbstract read
In one paragraph

Article in JAMA neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
16.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Dementia Prevalence, Incidence, and Mortality Trends Among U.S. Adults Ages 72 and Older, 2011-2021.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Necropolitics of Death in Neurodegeneration.Culture, medicine and psychiatry · 2024
    Review
  18. 2024 Alzheimer's disease facts and figures.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Ruijia ChenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco.
Marie-Laure CharpignonInstitute for Data, Systems, and Society, Massachusetts Institute of Technology, Cambridge.
Rafeya V RaquibDepartment of Global Health, Boston University School of Public Health, Boston, Massachusetts.
Jingxuan WangDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco.
Erika MezaDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco.
Hélène E AschmannDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco.
Michelle A DeVostDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco.
Alyssa MooneyInstitute for Health Policy Studies, University of California, San Francisco, San Francisco.
Kirsten Bibbins-DomingoDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco.
Alicia R RileyDepartment of Sociology, University of California, Santa Cruz, Santa Cruz.
Mathew V KiangDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California.
Yea-Hung ChenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco.
Andrew C StokesDepartment of Global Health, Boston University School of Public Health, Boston, Massachusetts.
M Maria GlymourDepartment of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.
University of California, San Francisco · USBoston University · USMassachusetts Institute of Technology · USStanford University · USUniversity of California, Santa Cruz · US

Funding

Reducing racial disparities in the treatment of opioid use disorder using machine learning-based causal analysisK99DA051534 · NIDA · STANFORD UNIVERSITY · PI KIANG, MATHEW VINHHOA · 2020 to 2021
$359k
Lifecourse Stressors and Social Disparities in Cognitive Aging: The Roles of Social Networks and Sleep DisturbanceK00AG068431 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, RUIJIA · 2021 to 2024
$330k
The impact of facility characteristics on racial disparities in ADRD mortality in nursing homesF31AG079651 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEVOST, MICHELLE ANNE · 2022 to 2023
$78k
NIA NIH HHS F31 AG079651NIA NIH HHS K00 AG068431NIDA NIH HHS K99 DA051534
6 · The paper itself

Abstract

Importance: Adults with Alzheimer disease and related dementias (ADRD) are particularly vulnerable to the direct and indirect effects of the COVID-19 pandemic. Deaths associated with ADRD increased substantially in pandemic year 1. It is unclear whether mortality associated with ADRD declined when better prevention strategies, testing, and vaccines became widely available in year 2. Objective: To compare pandemic-era excess deaths associated with ADRD between year 1 and year 2 overall and by age, sex, race and ethnicity, and place of death. Design, Setting, and Participants: This time series analysis used all death certificates of US decedents 65 years and older with ADRD as an underlying or contributing cause of death from January 2014 through February 2022. Exposure: COVID-19 pandemic era. Main Outcomes and Measures: Pandemic-era excess deaths associated with ADRD were defined as the difference between deaths with ADRD as an underlying or contributing cause observed from March 2020 to February 2021 (year 1) and March 2021 to February 2022 (year 2) compared with expected deaths during this period. Expected deaths were estimated using data from January 2014 to February 2020 fitted with autoregressive integrated moving average models. Results: Overall, 2 334 101 death certificates were analyzed. A total of 94 688 (95% prediction interval [PI], 84 192-104 890) pandemic-era excess deaths with ADRD were estimated in year 1 and 21 586 (95% PI, 10 631-32 450) in year 2. Declines in ADRD-related deaths in year 2 were substantial for every age, sex, and racial and ethnic group evaluated. Pandemic-era ADRD-related excess deaths declined among nursing home/long-term care residents (from 34 259 [95% PI, 25 819-42 677] in year 1 to -22 050 [95% PI, -30 765 to -13 273] in year 2), but excess deaths at home remained high (from 34 487 [95% PI, 32 815-36 142] in year 1 to 28 804 [95% PI, 27 067-30 571] in year 2). Conclusions and Relevance: This study found that large increases in mortality with ADRD as an underlying or contributing cause of death occurred in COVID-19 pandemic year 1 but were largely mitigated in pandemic year 2. The most pronounced declines were observed for deaths in nursing home/long-term care settings. Conversely, excess deaths at home and in medical facilities remained high in year 2.

Indexed as

Alzheimer DiseaseCOVID-19AdultHumansPandemics

Identifiers

PMID37459088
PMCPMC10352932
OpenAlexW4384522506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.